Potassium gluconate and Effexor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Potassium gluconate (potassium) and Effexor (venlafaxine hydrochloride). Common drug interactions include nasopharyngitis among females and seizure among males.

The phase IV clinical study analyzes what interactions people have when they take Potassium gluconate and Effexor. It is created by eHealthMe based on reports of 79 people who take the same drugs from the FDA, and is updated regularly.

What is Potassium gluconate?

Potassium gluconate has active ingredients of potassium. It is often used in hypokalemia. eHealthMe is studying from 2,901 Potassium gluconate users. Check the latest studies of Potassium gluconate.

What is Effexor?

Effexor has active ingredients of venlafaxine hydrochloride. It is often used in depression. eHealthMe is studying from 99,493 Effexor users. Check the latest studies of Effexor.

On Jul, 19, 2026

79 people who take Potassium gluconate and Effexor together, and have interactions are studied.

Potassium gluconate and Effexor drug interactions.

What are the common drug interactions of Potassium Gluconate and Effexor, by gender? *:

female:

Nasopharyngitis (inflammation of the nasopharynx)
Nephrolithiasis (calculi in the kidneys)
Neuropathy peripheral (surface nerve damage)
Oxygen saturation decreased
Parkinson's disease
Pneumonia
Post-traumatic stress disorder
Respiratory failure (inadequate gas exchange by the respiratory system)
Road traffic accident
Somnambulism (sleep walking)

male:

Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Blood potassium decreased
Sleep-related eating disorder (abnormal eating patterns during the night)
Fall
Diarrhoea
Loss of consciousness
Nausea (feeling of having an urge to vomit)
Cellulitis (infection under the skin)
Lethargy (tiredness)
Staphylococcal infection (an infection with staphylococcus bacteria)

What are the common drug interactions of Potassium Gluconate and Effexor, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Disability

40-49:

Contusion (a type of hematoma of tissue in which capillaries)
Dyspnoea (difficult or laboured respiration)
Eye swelling
Myalgia (muscle pain)
Pain of skin
Rash generalised (rash on most of body parts)
Urticaria (rash of round, red welts on the skin that itch intensely)

50-59:

Nausea (feeling of having an urge to vomit)
Peripheral swelling
Arthralgia (joint pain)
Asthenia (weakness)
Cardiac disorder
Cough
Diarrhoea
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Dyspnoea (difficult or laboured respiration)
Dyspnoea exertional (breathlessness or shortness of breath)

60+:

Breast cancer
Diarrhoea
Liver transplant rejection (failure of liver transplant)
Nausea (feeling of having an urge to vomit)
Vomiting
Cellulitis (infection under the skin)
Staphylococcal infection (an infection with staphylococcus bacteria)
Asthenia (weakness)
Biliary cirrhosis primary (primary biliary cirrhosis (pbc) is a long-term liver disease that damages the small bile ducts in the liver. the build-up of bile damages the liver)
Breast cancer female

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 46 people, 58.23%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 38 people, 48.10%
Drowsiness: 12 people, 15.19%
Pain: 10 people, 12.66%
High Blood Pressure: 7 people, 8.86%
Diarrhea: 6 people, 7.59%
Insomnia (sleeplessness): 5 people, 6.33%
Hypersensitivity: 4 people, 5.06%
High Blood Cholesterol: 4 people, 5.06%

* Approximation only. Some reports may have incomplete information.

Do you take Potassium gluconate and Effexor?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously